2024
A Patient With Type 1 Diabetes and Acute Rhinosinusitis
Roman F, Azar M, Trubin P. A Patient With Type 1 Diabetes and Acute Rhinosinusitis. JAMA 2024, 331: 1586-1587. PMID: 38630502, DOI: 10.1001/jama.2024.0642.Peer-Reviewed Original Research
2023
Response to comment on “Dosing implications for liposomal amphotericin B in pregnancy”
O'Grady N, Davis M, McManus D, Topal J, Azar M, Briggs N. Response to comment on “Dosing implications for liposomal amphotericin B in pregnancy”. Pharmacotherapy The Journal Of Human Pharmacology And Drug Therapy 2023, 43: 992-992. PMID: 37701938, DOI: 10.1002/phar.2864.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsDosing implications for liposomal amphotericin B in pregnancy
O'Grady N, McManus D, Briggs N, Azar M, Topal J, Davis M. Dosing implications for liposomal amphotericin B in pregnancy. Pharmacotherapy The Journal Of Human Pharmacology And Drug Therapy 2023, 43: 452-462. PMID: 36862037, DOI: 10.1002/phar.2784.Peer-Reviewed Original ResearchConceptsIdeal body weightLiposomal amphotericin BMucocutaneous leishmaniasisBody weightAmphotericin BInfectious Diseases SocietyTotal body weightPregnant patientsDiseases SocietyAmerica guidelinesPreferred agentPregnancyParasitic infectionsOpportunistic fungalAdverse effectsPatientsTreatmentLeishmaniasisLambsDaysUse of lambsGuidelinesRegimensWeightFetuses
2022
Real‐world experience with available, outpatient COVID‐19 therapies in solid organ transplant recipients during the omicron surge
Radcliffe C, Palacios CF, Azar MM, Cohen E, Malinis M. Real‐world experience with available, outpatient COVID‐19 therapies in solid organ transplant recipients during the omicron surge. American Journal Of Transplantation 2022, 22: 2458-2463. PMID: 35583664, PMCID: PMC9348251, DOI: 10.1111/ajt.17098.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsOral antiviral agentsOrgan transplant recipientsOutpatient therapyTransplant recipientsAntiviral agentsCOVID-19-related morbidityMonoclonal antibodiesKidney transplant recipientsRate of hospitalizationCOVID-19 therapyReal-world effectivenessSARS-CoV-2 pandemicCOVID-19 diagnosisModerate diseaseRetrospective reviewMean ageOutpatient settingClinical trialsSubstantial burdenTherapyCoronavirus diseaseMean timeHealthcare systemReal-world experience
2021
Increased Detection of Mycobacterium tuberculosis Disease Using a Tissue-Based Laboratory-Developed Polymerase Chain Reaction Assay Compared to Standard Diagnostics.
Mackow NA, Abi-Raad R, Kerantzas CA, Hui P, Malinis M, Azar MM. Increased Detection of Mycobacterium tuberculosis Disease Using a Tissue-Based Laboratory-Developed Polymerase Chain Reaction Assay Compared to Standard Diagnostics. American Journal Of Tropical Medicine And Hygiene 2021, 105: 1657-1661. PMID: 34544041, PMCID: PMC8641361, DOI: 10.4269/ajtmh.21-0104.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCulture TechniquesFemaleHumansLungLymph NodesMaleMiddle AgedMycobacterium tuberculosisPleuraReal-Time Polymerase Chain ReactionReference StandardsRetrospective StudiesSensitivity and SpecificitySputumTuberculosisTuberculosis, Lymph NodeTuberculosis, Multidrug-ResistantTuberculosis, PleuralTuberculosis, PulmonaryConceptsComposite reference standardMTB PCRAFB cultureMycobacterium tuberculosisPolymerase chain reactionAcid-fast bacilli smearMycobacterium tuberculosis diseasePositive AFB cultureChain reactionReal-time polymerase chain reactionStandard diagnosticsBacilli smearMTB casesTuberculosis diseaseClinical sensitivityLong turnaround timeXpertClinical performanceReference standardPCRVariable sensitivityTurnaround timeLymphPatientsTuberculosisA retrospective matched cohort single‐center study evaluating outcomes of COVID‐19 and the impact of immunomodulation on COVID‐19‐related cytokine release syndrome in solid organ transplant recipients
Ringer M, Azmy V, Kaman K, Tang D, Cheung H, Azar MM, Price C, Malinis M. A retrospective matched cohort single‐center study evaluating outcomes of COVID‐19 and the impact of immunomodulation on COVID‐19‐related cytokine release syndrome in solid organ transplant recipients. Transplant Infectious Disease 2021, 23: e13556. PMID: 33378571, PMCID: PMC7883059, DOI: 10.1111/tid.13556.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedCase-Control StudiesCohort StudiesComorbidityCOVID-19COVID-19 Drug TreatmentCytokine Release SyndromeFemaleGlucocorticoidsGraft RejectionHeart TransplantationHospitalizationHumansImmunologic FactorsImmunosuppressive AgentsInterleukin-10Interleukin-6Kidney TransplantationLiver TransplantationMaleMiddle AgedReceptors, Interleukin-2Retrospective StudiesSARS-CoV-2Severity of Illness IndexTreatment OutcomeYoung AdultConceptsCytokine release syndromeBody mass indexNon-SOT patientsSOT groupSOT patientsRelease syndromeInterleukin-6COVID-19-related cytokine release syndromeSoluble interleukin-2 receptor levelsControl groupInterleukin-2 receptor levelsSolid organ transplant patientsSolid organ transplant recipientsImpact of immunomodulationInterleukin-10 levelsOrgan transplant recipientsOrgan transplant patientsCritical care needsMulti-center studyCoronavirus disease 2019COVID-19Interleukin levelsIndex hospitalizationTransplant patientsTransplant recipients
2020
Clinicopathologic Features of Tissue Granulomas in Transplant Recipients: A Single Center Study in a Nontuberculosis Endemic Region.
Nussbaum EZ, Patel KK, Assi R, Raad RA, Malinis M, Azar MM. Clinicopathologic Features of Tissue Granulomas in Transplant Recipients: A Single Center Study in a Nontuberculosis Endemic Region. Archives Of Pathology & Laboratory Medicine 2020, 145: 988-999. PMID: 33290524, DOI: 10.5858/arpa.2020-0271-oa.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBartonellaBiopsyCommunicable DiseasesConnecticutCytomegalovirusFemaleGranulomaHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedOrgan TransplantationPrevalenceRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTransplantation, HomologousTreatment OutcomeYoung AdultConceptsEpidemiologic risk factorsPresence of symptomsInfectious etiologyAsymptomatic patientsTransplant recipientsTissue granulomasClinicopathologic featuresRisk factorsAllogeneic hematopoietic stem cell transplant recipientsHematopoietic stem cell transplant recipientsStem cell transplant recipientsYale-New Haven HospitalCommon infectious etiologiesLarge transplant populationCell transplant recipientsSingle-center studyCryptogenic organizing pneumoniaNew Haven HospitalRoutine disease surveillancePaucity of literatureCytomegalovirus hepatitisPosttransplant specimensBiopsy indicationOrganizing pneumoniaTransplant patientsClinical implications of SARS-CoV-2 cycle threshold values in solid organ transplant recipients
Gaston DC, Malinis M, Osborn R, Peaper DR, Landry M, Juthani-Mehta M, Azar MM. Clinical implications of SARS-CoV-2 cycle threshold values in solid organ transplant recipients. American Journal Of Transplantation 2020, 21: 1304-1311. PMID: 33043603, PMCID: PMC7675520, DOI: 10.1111/ajt.16357.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsOrgan transplant recipientsClinical implicationsCycle threshold valuesSOT patientsTransplant recipientsSymptom onsetYale New Haven Health SystemUpper respiratory tract samplesSARS-CoV-2 viral RNASARS-CoV-2 viral dynamicsAdult SOT recipientsRetrospective chart reviewRespiratory tract samplesSARS-CoV-2 cycle threshold valuesInfection prevention measuresCOVID-19 severityViral RNAHigher clinical acuityPrimary diagnostic testRT-PCR assaysSOT recipientsChart reviewViral loadAdmission severityTocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes
Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes. CHEST Journal 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.Peer-Reviewed Original ResearchConceptsCytokine release syndromeTocilizumab-treated patientsSevere diseaseRelease syndromeTocilizumab treatmentInflammatory biomarkersNonsevere diseaseSoluble IL-2 receptor levelsHigh-sensitivity C-reactive proteinIL-2 receptor levelsConsecutive COVID-19 patientsIL-6 receptor antagonistMechanical ventilation outcomesC-reactive proteinCOVID-19 patientsHigher admission levelsRace/ethnicityMV daysVentilation outcomesAdverse eventsChart reviewClinical responseMedian ageWhite patientsClinical outcomesDaptomycin perioperative prophylaxis for the prevention of vancomycin‐resistant Enterococcus infection in colonized liver transplant recipients
Sarwar S, Koff A, Malinis M, Azar MM. Daptomycin perioperative prophylaxis for the prevention of vancomycin‐resistant Enterococcus infection in colonized liver transplant recipients. Transplant Infectious Disease 2020, 22: e13280. PMID: 32216015, DOI: 10.1111/tid.13280.Peer-Reviewed Original ResearchConceptsLiver transplant recipientsDays of LTVRE infectionTransplant recipientsPerioperative prophylaxisRisk factorsLT periodVancomycin-resistant enterococcus infectionAntibiotic prophylaxis regimenDays post-LTAcute cellular rejectionPrimary graft failureLiver transplantation recipientsRenal replacement therapyRetrospective chart reviewIntensive care unitMultiple risk factorsVancomycin-resistant EnterococcusCellular rejectionLT morbidityPost-LTPre-LTProphylaxis regimenCause mortalityVRE bacteremia
2019
Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations
Shallis RM, Gleeson S, Azar M, Malinis M, Xu ML, Seropian SE, Gowda L, Zeidan AM. Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations. Leukemia & Lymphoma 2019, 60: 2584-2587. PMID: 30943051, DOI: 10.1080/10428194.2019.1594221.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2018
Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community
Springer SA, Di Paola A, Barbour R, Azar MM, Altice FL. Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 92-100. PMID: 29781884, PMCID: PMC6092223, DOI: 10.1097/qai.0000000000001759.Peer-Reviewed Original ResearchConceptsAlcohol use disorderViral suppressionExtended-release naltrexoneXR-NTXPlacebo groupPlacebo-controlled trialMonthly injectionsSecondary outcomesTreat analysisIncarcerated individualsEligible participantsWhite raceUse disordersAlcohol consumptionHIVMonthsNaltrexoneBaselineDisordersInjectionIncarcerated peopleParticipantsPlaceboGroupSuppressionExtended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community
Springer SA, Di Paola A, Azar M, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 43-53. PMID: 29373393, PMCID: PMC5889326, DOI: 10.1097/qai.0000000000001634.Peer-Reviewed Original ResearchMeSH KeywordsAdultCriminal LawDelayed-Action PreparationsDouble-Blind MethodFemaleFollow-Up StudiesHIV InfectionsHIV-1HumansInjections, IntramuscularMaleMiddle AgedMultivariate AnalysisNaltrexoneNarcotic AntagonistsOpioid-Related DisordersPrisonersProspective StudiesResearch DesignRNA, ViralTime FactorsTreatment OutcomeViral LoadConceptsOpioid use disorderViral suppressionXR-NTXPlacebo groupPrimary outcomeUse disordersXR-NTX groupPlacebo-controlled trialExtended-release naltrexoneStatistical significant differenceRelease naltrexoneMonthly injectionsEligible participantsTreatment groupsJail detaineesHIVMonthsBaselinePlaceboSignificant differencesNaltrexoneJail inmatesDisordersVS levelsOutcomesCentral nervous system histoplasmosis
Wheat J, Myint T, Guo Y, Kemmer P, Hage C, Terry C, Azar MM, Riddell J, Ender P, Chen S, Shehab K, Cleveland K, Esguerra E, Johnson J, Wright P, Douglas V, Vergidis P, Ooi W, Baddley J, Bamberger D, Khairy R, Vikram H, Jenny-Avital E, Sivasubramanian G, Bowlware K, Pahud B, Sarria J, Tsai T, Assi M, Mocherla S, Prakash V, Allen D, Passaretti C, Huprikar S, Anderson A. Central nervous system histoplasmosis. Medicine 2018, 97: e0245. PMID: 29595679, PMCID: PMC5895412, DOI: 10.1097/md.0000000000010245.Peer-Reviewed Original ResearchConceptsCentral nervous system histoplasmosisPercent of patientsCerebrospinal fluidAmphotericin BCentral nervous system involvementSingle-center case seriesNervous system involvementLiposomal amphotericin BCenter case seriesOutcome of treatmentAnti-Histoplasma antibodiesRecognition of infectionPatients 54 yearsCNS histoplasmosisDeoxycholate formulationDisseminated histoplasmosisMost patientsAntigen testingAntibody testingCase seriesImmunodeficiency syndromeHistoplasma antigenHistoplasmosis infectionSystem involvementYear survivalCase 1-2018: A 39-Year-Old Woman with Rapidly Progressive Respiratory Failure
Hibbert KA, Shepard JO, Lane RJ, Azar MM. Case 1-2018: A 39-Year-Old Woman with Rapidly Progressive Respiratory Failure. New England Journal Of Medicine 2018, 378: 182-190. PMID: 29320657, DOI: 10.1056/nejmcpc1712222.Peer-Reviewed Case Reports and Technical NotesMeSH KeywordsAdenoviridaeAdenoviridae InfectionsAdultAntiviral AgentsCidofovirCytosineDiagnosis, DifferentialFemaleHumansImmunocompromised HostLeukemia, Myeloid, AcuteLungNasopharynxOpportunistic InfectionsOrganophosphonatesRadiography, ThoracicRenal InsufficiencyRespiratory InsufficiencyStem Cell TransplantationTomography, X-Ray ComputedViral Load
2017
Clinical and epidemiological characterization of histoplasmosis cases in a nonendemic area, Connecticut, United States
Azar MM, Zhang X, Assi R, Hage C, Wheat LJ, Malinis MF. Clinical and epidemiological characterization of histoplasmosis cases in a nonendemic area, Connecticut, United States. Medical Mycology 2017, 56: 896-899. PMID: 29228334, DOI: 10.1093/mmy/myx120.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusHistoplasmosis casesEpidemiology of histoplasmosisNon-endemic areasSymptom onsetAntigen testingMedian timeImmunodeficiency virusActive histoplasmosisNonendemic areasRetrospective analysisEndemic areasEpidemiological characterizationHistoplasmosisNew HavenDaysPatientsEpidemiologyDiagnosisCasesCase 30-2017
Bhattacharyya RP, Flores EJ, Azar MM. Case 30-2017. New England Journal Of Medicine 2017, 377: 1274-1282. PMID: 28953442, DOI: 10.1056/nejmcpc1706100.Peer-Reviewed Case Reports and Technical NotesCase 26-2017
Letourneau AR, Price MC, Azar MM. Case 26-2017. New England Journal Of Medicine 2017, 377: 770-778. PMID: 28834480, DOI: 10.1056/nejmcpc1616402.Peer-Reviewed Case Reports and Technical NotesExtended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community
Springer SA, Di Paola A, Azar MM, Barbour R, Krishnan A, Altice FL. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug And Alcohol Dependence 2017, 174: 158-170. PMID: 28334661, PMCID: PMC5407009, DOI: 10.1016/j.drugalcdep.2017.01.026.Peer-Reviewed Original ResearchConceptsHeavy drinking daysAlcohol use disorderFirst heavy drinking dayExtended-release naltrexoneXR-NTXDrinking daysPlacebo groupAlcohol consumptionDrinks/drinking dayPlacebo-controlled trialSerious adverse eventsDrinks/daySignificant differencesMonthly injectionsAdverse eventsHIV diseaseHIV outcomesTreatment armsAlcohol scoresMAIN OUTCOMEAlcohol consumption scoresUse disordersImprovement scoresDrinking outcomesNaltrexone
2016
Disseminated Mycobacterium tuberculosis following renal transplant with alemtuzumab induction
Baghban A, Azar MM, Bernardo RM, Malinis M. Disseminated Mycobacterium tuberculosis following renal transplant with alemtuzumab induction. BMJ Case Reports 2016, 2016: bcr2016217998. PMID: 27852682, PMCID: PMC5129162, DOI: 10.1136/bcr-2016-217998.Peer-Reviewed Case Reports and Technical NotesConceptsMycobacterium tuberculosisDisseminated Mycobacterium tuberculosisIsoniazid preventative therapyHigh-risk patientsSolid organ transplantsOngoing risk factorsAlemtuzumab inductionDisseminated tuberculosisInduction immunosuppressionPeritransplant periodRenal transplantRenal transplantationPulmonary tuberculosisTuberculosis infectionPreventative therapyRisk factorsOrgan transplantsTuberculosisPatientsTransplantAvailable literatureImmunosuppressionTransplantationUnique challengesTherapy